---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-297978"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2022-12-05T23:59:59+00:00"
generated_at: "2026-06-21T09:58:53.716238+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru reports FY2022 net loss $83.8M; sabizabulin EUA faces FDA advisory panel 8-5 vote against

## Summary
- Full-year net loss $83.8M ($1.05 diluted EPS) vs net income $7.4M in FY2021.
- Total net revenues fell to $39.4M from $61.3M; FC2 product sales decline cited.
- R&D spending surged to $70.6M from $32.7M on sabizabulin and oncology programs.
- FDA advisory committee voted 8-5 against sabizabulin EUA; final FDA decision pending.
- Cash and equivalents $80.2M at Sept. 30, 2022, down from $122.4M a year earlier.

## SEC filing metadata
- accession: 0001193125-22-297978
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2022-12-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/0001193125-22-297978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/d384863d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-297978
- JSON: https://secwatch.observer/filing/0001193125-22-297978.json
- Plain text: https://secwatch.observer/filing/0001193125-22-297978.txt

## Key facts
- Earnings Releases
  VERU INC. reported financial results for fiscal 2022 fourth quarter and full year ended September 30, 2022.
  - Period: fiscal 2022 fourth quarter and full year ended September 30, 2022
  - Result: reported results
  source text: Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced financial results for its fiscal 2022 fourth quarter and full year ended September 30, 2022 and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/863894/000119312522297978/0001193125-22-297978-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.